0
Abstract: Poster Presentations |

A SINGLE DOSE OF FORADIL PROVIDES SIGNIFICANTLY GREATER BRONCHODILATION THAT MULTIPLE DOSES OF ALBUTEROL OVER 12 HOURS IN OLDER ASTHMATICS FREE TO VIEW

Umit Yegen, MD*; Denise Till, MS; Gregory P. Geba, MD
Author and Funding Information

Novartis Pharmaceuticals Corporation, East Hanover, NJ


Chest


Chest. 2005;128(4_MeetingAbstracts):246S-c-247S. doi:10.1378/chest.128.4_MeetingAbstracts.246S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  The efficacy of beta-agonists in elderly patients has not been extensively studied. We conducted a pooled analysis conducted across two 12-week, randomized, double-blind, double-dummy multicenter clinical trials to assess the efficacy of Foradil® (FOR) in an elderly subgroup population.

METHODS:  Forty patients ≥65 years of age with mild to moderate asthma had been randomized to receive formoterol (Foradil® dry powder inhalation capsules) 12μg b.i.d. (FOR12) or 24μg b.i.d. (FOR24) via the AerolizerTM, albuterol MDI 180μg q.i.d. (ALB) or placebo. FEV1 measurements were performed pre-dose, and 5, 15, 30 and 60 minutes and hourly through 12 hours post AM dose on the first day and every 4 weeks up to 12 weeks of treatment.

RESULTS:  Effect on FEV1 in the elderly subgroup receiving 12 or 24μg formoterol b.i.d. were similar to the general population, showing clinically significant bronchodilation (> 15% increase in FEV1) throughout the 12-hour interval, [area under the FEV1 curve (AUC; primary endpoint)].

CONCLUSION:  These results show that elderly patients with asthma achieved significantly greater and sustained bronchodilitation (>12 hours) with FOR than with multiple doses of ALB.

CLINICAL IMPLICATIONS:  The elderly population is a growing subgroup of patients that need to be further studied. This small sample of data investigates the efficacy and safety of formoterol in an elderly subgroup.

DISCLOSURE:  Umit Yegen, EmployeeAUC of FEV1 (L x hours)FOR12 v PlaceboFOR24 v PlaceboFOR12 v 24ALB v PlaceboAfter first dose4.50*4.71*-0.212.53After 12 weeks4.024.17-0.151.54*

Indicates statistical significance at the 0.05 level

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543